Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Clear Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT05176288
What this trial is testing

Avelumab, Palbociclib and Axitinib in Advanced RCC

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma
Bradley A. McGregor, MD
Testing effectiveness (Phase 2)Looking for participantsNCT05665361
What this trial is testing

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Who this might be right for
Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI) 100
Early research (Phase 1)Looking for participantsNCT07195916
What this trial is testing

Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Solid TumorsHematologic Malignancies
Incyte Corporation 280
Early research (Phase 1)Ended earlyNCT02543645
What this trial is testing

Varlilumab and Atezolizumab in Patients With Advanced Cancer

Who this might be right for
Carcinoma, Renal CellKidney DiseasesKidney Neoplasms+11 more
Celldex Therapeutics 18
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Looking for participantsNCT07123090
What this trial is testing

Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
Stephanie Berg 25
Testing effectiveness (Phase 2)Looking for participantsNCT06940518
What this trial is testing

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
IvonescimabClear Cell Renal Carcinoma
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT03075423
What this trial is testing

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Who this might be right for
Metastatic Renal Cell Carcinoma
Goethe University 316
Testing effectiveness (Phase 2)UnknownNCT00293501
What this trial is testing

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Who this might be right for
Kidney Cancer
University of Vermont 35
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Ended earlyNCT04300140
What this trial is testing

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Aravive, Inc. 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07277972
What this trial is testing

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Who this might be right for
RCC, Renal Cell Cancer
Tianjin Medical University Cancer Institute and Hospital 36
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Testing effectiveness (Phase 2)Ended earlyNCT00131651
What this trial is testing

ATN-161 in Advanced Renal Cell Cancer

Who this might be right for
Carcinoma, Renal Cell
Attenuon 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT06245915
What this trial is testing

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
Arsenal Biosciences, Inc. 37
Early research (Phase 1)UnknownNCT06049030
What this trial is testing

HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd. 190
Early research (Phase 1)Looking for participantsNCT05433142
What this trial is testing

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Xencor, Inc. 307
Early research (Phase 1)Looking for participantsNCT07300241
What this trial is testing

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more
Neomorph, Inc 30
Next Page